The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a a ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...